Clinical Trials in Nashville

Showing 2321-2340 of 9,711 trials

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

NCT01937117

This research is being done to determine if early changes on a type of imaging procedure called PET (Positron Emission Tomography) can predict which patients are most likely to respond to the combination of trastuzumab and pertuzumab when given prior to surgery.

Breast Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins88 participantsStarted Jan 2014

Birmingham, Alabama, United States • Washington D.C., District of Columbia, United States • Indianapolis, Indiana, United States +7 more locations

RECRUITINGPhase 1< 1 mile

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

NCT06415487

ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR). The ACE2016-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, persistency, pharmacodynamics and efficacy of ACE2016 in patients with Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR).

Locally Advanced Solid TumorMetastatic Solid Tumor

Acepodia Biotech, Inc.30 participantsStarted Aug 2024

San Diego, California, United States • Denver, Colorado, United States • Nashville, Tennessee, United States +6 more locations

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

Find Trials by Condition in Nashville

Project PAIR: Parent-implemented Articulation Intervention With Recast

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Gluten Technology and Education for Celiac Health

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

The Biomarkers in the Hyperbaric Oxygen Brain Injury Treatment Trial (BioHOBIT)

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Vaginal Ecosystem and Network in the United States Study

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

FS120 Phase 1/1b Study in Patients With Advanced Malignancies

Cough Reduction in IPF With Nalbuphine ER

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates